

Nancy L. Bartlett

For the last 30 years, my research has focused on the design, conduct, and analysis of clinical trials evaluating new treatments for patients with lymphoma. I have served as the Principal Investigator of the Washington University CALGB/Alliance/NCTNU10/LAPS grants for the last 25 years, engaging senior, mid-level, and junior investigators in the NCTN mission in multiple disciplines and disease sites. We have distinguished ourselves as one of the highest Alliance/NCTN accruing sites, consistently in the top five, as well as receiving routine commendations by audit teams for our excellent trial conduct. In addition, I have served as the Vice-Chair of the CALGB/Alliance Lymphoma Committee for more than 10 years, where I have served as PI or Co-PI of several Phase II studies and mentored young investigators during trial design and analysis. At Washington University, I help oversee the lymphoma clinical research team including a team of more than 20 clinical research assistants. In addition to my leadership roles, I personally enroll and treat more than 60 patients a year on therapeutic clinical trials allowing me to better understand the impact of trial design on study feasibility and conduct and providing me an opportunity to mentor and educate trainees and young faculty about the importance of clinical trials. In 2014, I chaired the Hodgkin lymphoma working group at the Clinical Trials Planning Meeting, culminating in a manuscript outlining the priorities for HL trials in the NCTN.